A weekly injection already known for melting away pounds may also quiet one of the loudest problems in the bedroom: chronic snoring and breathing pauses tied to obstructive sleep apnea.
Story Snapshot
- Two new phase 3 trials tested retatrutide, an experimental weekly injection, in adults with moderate-to-severe obstructive sleep apnea.
- Patients saw major drops in breathing interruptions during sleep, measured by a standard score called the apnea-hypopnea index.
- The drug worked in people with and without type 2 diabetes, across two separate 80-week studies.
- Retatrutide is still investigational, meaning it has not yet won approval specifically for sleep apnea.
What The New Trials Actually Measured
Researchers published results from two studies called TRIUMPH-1-OSA and TRIUMPH-2-OSA in the New England Journal of Medicine. Both trials were randomized, double-blind, and placebo-controlled, the gold standard for medical research. Participants had moderate-to-severe obstructive sleep apnea and a body mass index of at least 27. Doctors tracked how often breathing paused or shallowed each hour during sleep, a measurement called the apnea-hypopnea index, or AHI.
In the trial without diabetic patients, people taking retatrutide saw their AHI drop by 22.9 to 34.3 events per hour, depending on dose. The placebo group only dropped by 9.9 events per hour. That left a placebo-adjusted improvement as high as 24.4 events per hour at the middle dose, a gap too large to chalk up to chance.
Results Held Up In Diabetic Patients Too
The second trial enrolled 448 people with type 2 diabetes, a group that often struggles more with weight loss and sleep apnea together. Even here, retatrutide beat placebo by 8.9 to 15.1 events per hour depending on dose, according to the published data. The higher two doses hit strong statistical significance, with a p-value under 0.001, meaning the odds of this happening by random chance were extremely low.
Both trials ran for 80 weeks, well over a year, which matters because short drug trials sometimes show results that fade once the body adjusts. A year and a half of sustained improvement gives doctors more confidence this effect is not a fluke tied to the first few months of treatment.
Why Weight Loss And Breathing Are So Tightly Linked
Obstructive sleep apnea happens when soft tissue in the throat collapses during sleep, blocking airflow. Extra weight around the neck and airway is one of the biggest drivers of that collapse. Retatrutide was originally built as an obesity drug, and earlier company data showed patients on the highest dose lost an average of 70.3 pounds, or 28.3 percent of their body weight, over the same 80-week window.
That overlap raises an honest question doctors are already debating: is the sleep benefit mostly a side effect of shedding pounds, or does the drug do something extra for the airway itself? The published trial results do not separate those two effects, so the exact mechanism remains an open scientific question rather than a settled one.
This Is Not The First Drug To Try This
Retatrutide is not working alone in this space. The Food and Drug Administration already approved Eli Lilly’s tirzepatide, sold as Zepbound, as the first prescription medicine specifically for moderate-to-severe sleep apnea in adults with obesity. That approval came from a separate trial showing meaningful symptom relief over a year, with or without standard breathing machines. Retatrutide adds a third hormone pathway to the mix, which may explain its larger reported effect sizes compared to earlier drugs in this class.
Doctors have long known that losing weight helps sleep apnea, but results have historically been inconsistent and harder to achieve through diet and exercise alone. A medication that reliably drives both weight loss and measurable airway improvement gives physicians a new tool, especially for patients who have struggled to tolerate a CPAP machine every night.
What Still Has To Happen Before This Reaches Pharmacies
Retatrutide remains investigational, meaning it is not yet approved for sleep apnea or any other condition in the United States. Eli Lilly’s own reporting on its drug pipeline states the data package is now complete for regulatory submissions covering obesity, sleep apnea, and knee osteoarthritis pain, with a formal application expected to follow. Until that approval comes through, standard treatments like CPAP machines and weight-management programs remain the backbone of sleep apnea care, and the new data should be read as a promising step forward rather than a finished solution.
Sources:
mindbodygreen.com, nejm.org, emjreviews.com
